The global acquired immunodeficiency syndrome (AIDS) treatment market size was valued at USD 35.33 billion in 2024 and is expected to reach USD 47.61 billion by 2032, at a CAGR of 3.80% during the forecast period
The market growth is primarily driven by the increasing global prevalence of HIV infections, combined with improved access to antiretroviral therapy (ART) in both developed and developing regions
In addition, continuous advancements in treatment regimens, including long-acting injectables and novel combination therapies, are transforming patient outcomes and compliance, thereby strengthening market expansion. These medical and public health developments are significantly accelerating the global adoption of effective AIDS treatment solutions, fueling industry growth